Seibert, Stephan R <br/><br/>
Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.  [electronic resource] 

 -  Clinical transplantation  12 2018 
 - e13424 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1399-0012 
<br/><br/><label>Standard No.: </label>10.1111/ctr.13424  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Black or African American--genetics<br/>Aged<br/>Aged, 80 and over<br/>Cytochrome P-450 CYP3A--genetics<br/>Dose-Response Relationship, Drug<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Graft Rejection--drug therapy<br/>Graft Survival--drug effects<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Incidence<br/>Kidney Failure, Chronic--surgery<br/>Kidney Transplantation--adverse effects<br/>Male<br/>Middle Aged<br/>Minnesota--epidemiology<br/>Postoperative Complications<br/>Prognosis<br/>Prospective Studies<br/>Risk Factors<br/>Tacrolimus--therapeutic use<br/>White People--genetics<br/>Young Adult